viewBiocept Inc

Biocept launches its CNSide cerebrospinal fluid assay for early detection of metastatic brain cancer

The company said the assay has the ability to offer a timely and accurate method to diagnose disease and assess response to therapy

Biocept Inc -
Biocept said CNSide represents a significant market opportunity that it estimates at more than $1 billion annually in the US

Biocept Inc (NASDAQ:BIOC) (FRA:B003) announced the full commercial launch of CNSide, the company’s cerebrospinal fluid (CSF) assay designed to better detect and manage the treatment of metastatic cancers involving the central nervous system (CNS).  

The company said the assay, which was initially introduced in January 2020, has the ability to offer a timely and accurate method to diagnose disease, identify actionable biomarkers, and assess response to therapy, potentially impacting life expectancy and quality of life. 

“The full salesforce launch of our CSF assay, along with new branding, is an exciting next step toward our goal of establishing CNSide as a new standard-of-care diagnostic test for cerebrospinal fluid,” Biocept CEO Michael Nall said in a statement.   

READ: Biocept changing the way physicians examine blood work for their cancer patients and doing coronavirus testing

“Initial acceptance by neuro-oncology early-adopters has been highly encouraging as physicians from nearly two dozen leading academic institutions have ordered CNSide — with many becoming repeat users,” Nall added.  

“This represents a significant market opportunity that we estimate at more than $1 billion annually in the United States for breast and lung cancers that have metastasized to the central nervous system.”

Biocept also noted that in 2020, it presented highly favorable results from pilot studies with the assay at three major scientific meetings, which showed that in about 80% of the cases of suspected CNS involvement, tumor cells were detected using the CNSide assay, compared with about 50% of cases examined by CSF cytology.

It added that the assay is currently validated to identify metastatic cancers originating in the lung and breast. The company said it plans to expand its CSF testing menu for additional tumor types and biomarkers in the future.

Biocept is a molecular diagnostics company focused on changing the way physicians examine blood in their patients with cancer.

The San Diego-based company sells CEE-Sure blood collection tubes and has also developed a patented liquid biopsy technology called Target Selector that detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA).

Contact Sean at sean@proactiveinvestors.com

Quick facts: Biocept Inc


Price: 4.07 USD

Market Cap: $59.92 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Biocept approved for expanded Medicare coverage for its Target Selector...

Biocept Inc (NASDAQ:BIOC) (NASDAQ:BIOC) (FRA:B003) CEO Mike Nall tells Proactive it has received a positive final Local Coverage Determination from the Centers for Medicare & Medicaid Services Molecular Diagnostics Program, which will expand Medicare coverage for use of Biocept’s Target...

on 07/27/2021

2 min read